Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • weightbayou weightbayou Sep 28, 2012 6:21 PM Flag

    "We are extremely pleased with the.......

    The CEO should have said something about approval of Dacogen today in the EU like he did about HSP90.

    "We are extremely pleased with the initiation of our HSP90 inhibitor study in prostate cancer patients. With the incidence of prostate cancer in the U.S. at 215,000, and 28,000 deaths annually, this is a disease which is the second leading cause of cancer death among American men," said James S.J. Manuso, PhD, chairman & chief executive officer. "Despite developments in the treatment landscape, prostate cancer patients will continue to need new products, particularly ones that might be used in combination with other therapies, during the course of their disease."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT